Evoke Pharma, Inc. (EVOK)
Evoke Pharma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Solana Beach, CA, US. The stock last traded at $11.00, up 0.00% on the session, giving a market capitalisation of $18.9M. On trailing twelve-month figures it carries a trailing P/E of -6.96, a net margin of -36.3%. Its beta of -0.14 implies it has historically moved less than the broad market.
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.
Evoke Pharma, Inc. is most often compared with the following Healthcare names: